PROGENICS PHARMACEUTICALS IN - COM (PGNX)

CUSIP: 743187106

Q4 2016 13F Holders as of 31 Dec 2016

Type / Class
Equity / COM
Total 13F shares
59,960,484
Share change
-237,973
Total reported value
$518,057,513
Put/Call ratio
49%
Price per share
$8.64
Number of holders
124
Value change
+$2,600,473
Number of buys
63
Number of sells
61

Quarterly Holders Quick Answers

What is CUSIP 743187106?
CUSIP 743187106 identifies PGNX - PROGENICS PHARMACEUTICALS IN - COM in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of PROGENICS PHARMACEUTICALS IN - COM (PGNX) as of Q4 2016

As of 31 Dec 2016, PROGENICS PHARMACEUTICALS IN - COM (PGNX) was held by 124 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 59,960,484 shares. The largest 10 holders included FEDERATED INVESTORS INC /PA/, Broadfin Capital, LLC, FMR LLC, BlackRock Fund Advisors, BAKER BROS. ADVISORS LP, VANGUARD GROUP INC, EAGLE ASSET MANAGEMENT INC, PINNACLE ASSOCIATES LTD, STATE STREET CORP, and BlackRock Institutional Trust Company, N.A.. This page lists 124 institutional shareholders reporting positions in this security for the Q4 2016 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.